更新于：2024-11-21

Hextend

更新于：2024-11-21

概要

研发状态

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

免疫系统疾病血液及淋巴系统疾病其他疾病

在研适应症

输血反应血容量不足

非在研适应症-

原研机构

Lineage Cell Therapeutics, Inc.

在研机构

Lineage Cell Therapeutics, Inc.

HK inno.N Corp.

Hospira, Inc.

非在研机构

Summit Pharmaceuticals International Corp.

Maruishi Pharmaceutical Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1999-03-31),

血容量不足

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

项与 Hextend 相关的临床试验

NCT01713166 / CompletedN/AIIT

Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery

The purpose of this study is to compare the effects of crystalloid and colloid, which are used for pump priming solution, on the microcirculatory alterations during cardiac surgery.

开始日期2013-03-01

申办/合作机构

Seoul National University Hospital

NCT00983281 / CompletedN/AIIT

Use of Hextend in Trauma

This is a chart review of all trauma patients during the specified time period. The purpose of this study is to examine the effects of resuscitation with hextend after trauma, in the adult population. The authors hypothesize that when compared to patients resuscitated with standard of care, resuscitation with Hextend will result in a mortality difference.

开始日期2008-08-01

申办/合作机构

University of Miami

NCT00467922 / Completed临床3期IIT

A Randomized Prospective Double Blind Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care Versus Either Colloid and Crystalloid

The purpose of this study is to find out if guided fluid administration with the esophageal monitor is superior to standard fluid administration and whether use of the hetastarch or lactated ringers offers different benefits with respect to length of stay in the hospital after hand-assisted colorectal surgery.

开始日期2007-05-01

申办/合作机构

Spectrum Health Hospitals, Inc.

[+1]

100 项与 Hextend 相关的临床结果

登录后查看更多信息

100 项与 Hextend 相关的转化医学

登录后查看更多信息

100 项与 Hextend 相关的专利（医药）

登录后查看更多信息

112

项与 Hextend 相关的文献（医药）

2024-07-29·Angewandte Chemie International Edition

Engineering Low Volume Resuscitants for the Prehospital Care of Severe Hemorrhagic Shock

Article

作者: Ringgold, Kristyn M. ; Pichon, Trey J. ; Lu, Maggie ; Stucky, Sarah ; Mickelson, Ethan E. ; Huang, Wen‐Chia ; Pozzo, Lilo D. ; S. John, Alexander E. ; Wang, Xu ; White, Nathan J. ; Snyder, Jessica M. ; Pun, Suzie H. ; Ling, Melissa ; Hilburg, Shayna L.

AbstractGlobally, traumatic injury is a leading cause of suffering and death. The ability to curtail damage and ensure survival after major injury requires a time‐sensitive response balancing organ perfusion, blood loss, and portability, underscoring the need for novel therapies for the prehospital environment. Currently, there are few options available for damage control resuscitation (DCR) of trauma victims. We hypothesize that synthetic polymers, which are tunable, portable, and stable under austere conditions, can be developed as effective injectable therapies for trauma medicine. In this work, we design injectable polymers for use as low volume resuscitants (LVRs). Using RAFT polymerization, we evaluate the effect of polymer size, architecture, and chemical composition upon both blood coagulation and resuscitation in a rat hemorrhagic shock model. Our therapy is evaluated against a clinically used colloid resuscitant, Hextend. We demonstrate that a radiant star poly(glycerol monomethacrylate) polymer did not interfere with coagulation while successfully correcting metabolic deficit and resuscitating animals from hemorrhagic shock to the desired mean arterial pressure range for DCR – correcting a 60 % total blood volume (TBV) loss when given at only 10 % TBV. This highly portable and non‐coagulopathic resuscitant has profound potential for application in trauma medicine.

2024-01-23·Military Medicine

Transition of Resuscitative Endovascular Balloon Occlusion of the Aorta from Zone 3 to Zone 1 to Treat Hemodynamic Collapse during Continued Hemorrhage

Article

作者: Sandoval, Melody L ; Causey, Marlin W ; Baker, Kimberly J ; Flinn, Ashley N ; Rall, Jason M

ABSTRACTIntroductionNoncompressible torso hemorrhage (NCTH) accounts for most potentially survivable deaths on the battlefield. Treatment of NCTH is challenging, especially in far-forward environments with limited capabilities. Resuscitative endovascular balloon occlusion of the aorta (REBOA) has shown promise in the care of patients with NCTH. REBOA involves introducing a balloon catheter into the descending aorta in a specific occlusion region (zones 1, 2, or 3) and acts as a hemorrhage control adjunct with resuscitative support. The balloon is placed in zone 3 in the infrarenal aorta for high junctional or pelvic injuries and in zone 1 proximal to the diaphragm for torso hemorrhage. Zone 1 REBOA provides more resuscitative support than zone 3; however, the potential for ischemia and reperfusion injuries is greater with zone 1 than with zone 3 REBOA placement. This study aims to determine the possible benefit of transitioning the REBOA balloon from zone 3 to zone 1 to rescue a patient with ongoing venous bleeding and impending cardiovascular collapse.Materials and MethodsYorkshire male swine (70–90 kg, n = 6 per group) underwent injury to the femoral artery, which was allowed to bleed freely for 60 s, along with a simultaneous controlled venous hemorrhage. After 60 s, the arterial bleed was controlled with hemostatic gauze and zone 3 REBOA was inflated. Five hundred milliliters of Hextend was used for initial fluid resuscitation. The controlled venous bleed continued until a mean arterial pressure (MAP) of 30 mmHg was reached to create an impending cardiovascular collapse. The animals were then randomized into either continued zone 3 REBOA or transition from zone 3 to zone 1 REBOA. Following 30 min, a “hospital phase” was initiated, consisting of cessation of the venous hemorrhage, deflation of the REBOA balloon, and transfusion of one unit of whole blood administered along with saline and norepinephrine to maintain a MAP of 60 mmHg or higher. The animals then underwent a 2-h observation period. Survival, hemodynamics, and blood chemistries were compared between groups.ResultsNo significant differences between groups were observed in hemodynamic or laboratory values at baseline, postinitial injury, or when MAP reached 30 mmHg. Survival was significantly longer in animals that transitioned into zone 1 REBOA (log-rank analysis, P = .012). The average time of survival was 14 ± 10 min for zone 3 animals vs. 65 ± 59 min for zone 1 animals (P = .064). No animals in the zone 3 group survived to the hospital phase. Zone 1–treated animals showed immediate hemodynamic improvement after transition, with maximum blood pressure reaching near baseline values compared to those in the zone 3 group.ConclusionsIn this swine model of NCTH, hemodynamics and survival were improved when the REBOA balloon was transitioned from zone 3 to zone 1 during an impending cardiovascular collapse. Furthermore, these improved outcome data support the pursuit of additional research into mitigating ischemia–reperfusion insult to the abdominal viscera while still providing excellent resuscitative support, such as intermittent or partial REBOA.

2023-05-01·Journal of Surgical Research

Characterization of Combined Blast- and Fragment-Induced Pelvic Injuries and Hemostatic Resuscitation in Rabbits

Article

作者: Jiang, Renqing ; Yang, Haoyang ; Ye, Zhao ; Zhong, Xin ; Zong, Zhaowen ; Du, Wenqiong ; Jia, Yijun ; Zhou, Xiaolin

INTRODUCTIONTo establish a blast- and fragment-induced pelvic injury animal model in rabbits, observe its injury characteristics, and explore the effects of hemostatic resuscitation combined with damage control surgery (DCS) with respect to this injury model.METHODSForty-eight rabbits were randomly allocated to four groups: group A rabbits were subjected to pelvic injury, group B rabbits to pelvic injury + DCS, group C rabbits to pelvic injury + DCS + resuscitation with Hextend, and group D rabbits to pelvic injury + DCS + Hextend + hemostatic resuscitation with tranexamic acid, fibrinogen concentrate, and prothrombin complex concentrate. Simulated blast and fragment-induced pelvic injury was produced by a custom-made machine. We implemented CT scanning and necropsy to assess the injury state and calculated the coefficient of variation (CV) of the cumulative abbreviated injury scale (AIS) to assess the reproducibility of the animal model. Immediately after instrumentation (0 h), and 1 h, 2 h, 4 h, and 8 h after injury, blood samples were taken for laboratory tests.RESULTSWe found that severe pelvic injury was produced with an AIS CV value of 10.32%, and the rabbits demonstrated severe physiologic impairment and coagulo-fibrinolytic derangements with high mortality. In rabbits of group D, however, physiologic and coagulo-fibrinolytic parameters were significantly enhanced with improved organ function and lowered mortality when compared with the other three groups.CONCLUSIONSWe herein established in rabbits a blast- and fragment-induced pelvic injury animal model that exhibited high reproducibility, and we demonstrated that hemostatic resuscitation plus DCS was effective in improving the outcome.

项与 Hextend 相关的新闻（医药）

2011-08-10

·BioSpace

BioTime Announces Second Quarter 2011 Financial Results and Corporate Developments

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the quarter ended June 30, 2011 and provided an update on corporate developments. For the quarter ended June 30, 2011, total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income) was $756 thousand, up 11% from $680 thousand for the same period one year ago. The increase in revenue year-over-year in the second quarter 2011 is primarily attributable to a significant increase in research product sales and an increase in grant income. The increase in second quarter revenue was offset, to a degree, by a decrease in royalties from the sale of Hextend®, BioTime’s blood plasma expander product, and license fees related to Hextend and other plasma expander products under development.

财报

100 项与 Hextend 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	B05XX	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
输血反应	加拿大	Hospira, Inc.	2004-05-13
输血反应	加拿大	Lineage Cell Therapeutics, Inc.	2004-05-13
血容量不足	美国	Hospira, Inc.	1999-03-31